The bottom line is that they fell to the Tigers 3-2 and a loss is not what you’re looking for… they saw 20 of those last September.
However, there were some good signs in this one:
–For all the talk there will be about the new Sox closer Alfedo Aceves failing in his first outing, the Sox got to Tiger closer Jose Valverde for two runs in the 9th inning. Valverde was 49-for-49 in closing situations last season. Dustin Pedroia started things off with a double and later Ryan Sweeney came up with a huge two-out triple to tie things up. Had to feel good for Sweeney and that ball didn’t miss going out by much. And for that matter, Cody Ross drilled a line drive right to short after Sweeney’s triple. That would have driven in the go-ahead run.
Dan Roche Video Blog:
–Jon Lester was impressive. Lester gutted through seven innings giving up just one run. He got double play balls and other big outs when he needed "
Click here to read the whole article
... with the option to cross over at signs of disease progression. Most patients had disease control on dabrafenib. Best confirmed response rates with the drug and with chemotherapy, respectively were: With just 12% of patients having died, ...Read more
Avastin, sold by Roche, is approved as a first-line or second-line treatment for colorectal cancer, but not for both. Sales of the drug, also known as bevacizumab, totaled $5.3 billion Swiss francs ($5.5 billion) last year.Read more
TUCSON, Ariz., May 31, 2012 /PRNewswire via COMTEX/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, has signed an exclusive license agreement with the German Cancer Research Center (Deutsches Krebsforschungszentrum, ...Read more
Roche Holding AG's Genentech unit has won the right to try its experimental Alzheimer's drug crenezumab on people with no signs of dementia - the first such trial to gauge whether early intervention can help prevent or slow the disease.Read more